Got Doxy- 'Flipping the Script' on STI PEP

StatusRecruiting

PhasePhase 4

SponsorEmory University

Started2025-10-13

View on ClinicalTrials.gov ↗

Amendment history

2026-04-26

Study Status v3

Start date2025-10-22→2025-10-13

2026-04-20

Study Status v2

Primary completion date2028-09→2029-04-13

Completion date2028-09→2029-04-13

2025-12-09

Not Yet Recruiting→Recruiting Study Identification, Study Status, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-11→confirmed 2025-10-22

Eligibility criteria+60 characters

[...] ent viral load documented <50 copies/ml and the most recent cluster of differentiation 4 (CD4)>300cells/ul For people without HIV, taking oral daily, oral [...] co-infections), as assessed by the investigator. History of inflammatory bowel disease (IBD) or other inflammatory, infiltrative, infectious, or vascula [...]

Secondary endpointsdetails revised at 1 of 2 entries

Study sitesdetails revised at 2 of 2 sites

2025-10-03

Original filing

Emory University

371 trials monitored

See 23 trials at risk

This study is being done to test the effects of doxycycline on inflammation and the bacteria in the body in people with HIV and in people on HIV pre-exposure prophylaxis. This drug is approved by the Food and Drug Administration (FDA) for the treatment of bacterial infections. The study team will investigate whether the drug has additional effects on inflammation or on the bacteria that live in the body.

Trial Details

NCT Number	NCT07215325
Lead Sponsor	Emory University Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions	Sexually Transmitted Infections (STI)
Enrollment	200 participants
Start Date	2025-10-13
Primary Completion	2029-04-13 (estimated)
Study Completion	2029-04-13 (estimated)
Updated on ClinicalTrials.gov	2026-04-30